½ÃÀ庸°í¼­
»óǰÄÚµå
1660915

Á¶Á¦ ¾à±¹ ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)

Compounding Pharmacies Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Persistence Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 245 Pages | ¹è¼Û¾È³» : 2-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Á¶Á¦ ¾à±¹ ½ÃÀå ±Ô¸ð´Â 2025³â¿¡ 114¾ï ´Þ·¯·Î 2025-2032³â ¿¹Ãø ±â°£ µ¿¾È 5.2%ÀÇ CAGR·Î È®´ëµÇ¾î 2032³â¿¡´Â 163¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶Á¦ ¾à±¹Àº ȯÀÚÀÇ Æ¯Á¤ ¿ä±¸¿¡ ¸Â´Â ¸ÂÃãÇü ÀǾàǰÀ» ¸¸µå´Â °ÍÀ» Àü¹®À¸·Î Çϸç, ´ëü Á¦Çü, ¾Ë·¹¸£°ÕÀÌ ¾ø´Â ÀǾàǰ ¶Ç´Â ½ÃÆÇµÇÁö ¾Ê´Â ÀǾàǰÀÇ Á¶ÇÕÀ» ÇÊ¿ä·Î ÇÏ´Â °³ÀÎÀ» À§ÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ÀÌµé ¾à±¹Àº º´¿ø, Àü¹® Ŭ¸®´Ð, Àå±â¿ä¾ç½Ã¼³, °³ÀΠȯÀÚ¸¦ ´ë»óÀ¸·Î ¿Ü¿ë Å©¸², ÁÖ»çÁ¦, °æ±¸¿ë ¾×Á¦, ¼Ò¾Æ¿ë ¾àǰ µî ´Ù¾çÇÑ Á¦ÇüÀ» Á¦°øÇÕ´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀǾàǰ ºÎÁ· ½ÉÈ­, Ư¼öÇÑ Ä¡·á¸¦ ÇÊ¿ä·Î ÇÏ´Â ¸¸¼ºÁúȯÀÇ È®»êÀÔ´Ï´Ù.

¼¼°è Á¶Á¦ ¾à±¹ ½ÃÀåÀº ȯÀÚº° ¸ÂÃã ÀÇ·á¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¾Ï, ½ÉÇ÷°üÁúȯ, È£¸£¸ó ºÒ±ÕÇü°ú °°Àº ¸¸¼ºÁúȯÀÇ ¹ßº´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ëÀÎ Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ Åõ¿©°¡ ¿ëÀÌÇÑ ´ëü Á¦Á¦°¡ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. Á¶Á¦ ¾à±¹¿¡ ´ëÇÑ ±ÔÁ¦ Áö¿ø°ú ¹«±Õ Á¶Á¦ ¹× ¾à¹° ¹èÇÕ ÀÚµ¿È­¿Í °°Àº ¾à¹° ¹èÇÕ ±â¼úÀÇ ¹ßÀüÀº ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÁ¤ Çʼö ÀǾàǰÀÇ ºÎÁ·À¸·Î ÀÎÇØ ƯÈ÷ º´¿ø ¹× Àü¹® ÀÇ·á ÇöÀå¿¡¼­ ¹èÇÕ ÀǾàǰ¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

Á¶Á¦ ¾à±¹ ½ÃÀåÀº ÇコÄɾî ÁöÃâ Áõ°¡, Á¶Á¦ ±â¼ú ¹ßÀü, ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µîÀ» ¹è°æÀ¸·Î Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀçÅÃÀÇ·á ¼­ºñ½º ¹× ¿ø°ÝÀÇ·á Ç÷§ÆûÀÇ È®´ë·Î ȯÀÚµéÀº Á¶Á¦ ÀǾàǰÀ» Æí¸®ÇÏ°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ 3D ¾à¹° Àμâ, ³ª³ë±â¼ú ±â¹Ý Á¦Çü, ¾à¹° ¸ÂÃãÈ­¿¡¼­ ÀΰøÁö´ÉÀÇ ÅëÇÕ µî Á¶Á¦ ±â¼úÀÇ Çõ½ÅÀº ½ÃÀå ÁøÀÔ ±â¾÷¿¡°Ô »õ·Î¿î ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. R&D¿¡ ´ëÇÑ ÅõÀÚ¿Í ÇÔ²² Á¶Á¦ ¾à±¹ ¹× ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿ÍÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀº »õ·Î¿î ±âȸ¸¦ Ȱ¿ëÇϰí ÁøÈ­ÇÏ´Â ÀÌ »ê¾÷¿¡¼­ ½ÃÀå ¸®´õ½ÊÀ» À¯ÁöÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

¼¼°èÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, Á¦Ç°º°, ¿ëµµº°, Ä¡·á ºÐ¾ßº°, Áö¿ªº° µ¿Çâ, ½ÃÀå ÁøÀÔ ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå °³¿ä

Á¦3Àå ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå Çٽɼº°ø¿äÀÎ

Á¦5Àå ½ÃÀå ¹è°æ

  • °Å½Ã°æÁ¦ ¿äÀÎ
  • ¿¹Ãø¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
  • ½ÃÀå ¿ªÇÐ

Á¦6Àå COVID-19 À§±â ºÐ¼®

Á¦7Àå ¼¼°èÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå ¼ö¿ä(±Ô¸ð, 10¾ï ´Þ·¯) ºÐ¼®, 2019-2032³â

  • °ú°Å ½ÃÀå ±Ý¾×(10¾ï ´Þ·¯) ºÐ¼®, 2019-2024³â
  • ÇöÀç ¹× ÇâÈÄ ½ÃÀå ±Ý¾×(10¾ï ´Þ·¯) ¿¹Ãø, 2025-2032³â

Á¦8Àå ¼¼°èÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå ºÐ¼®, 2019-2032³â, Á¦Ç°º°

  • °ú°Å ½ÃÀå ±Ô¸ð(°¡Ä¡ ¶Ç´Â ±Ô¸ð, 10¾ï ´Þ·¯) µ¿Çâ, Á¦Ç°º°, 2019-2024³â
  • ÇöÀç ¹× ÇâÈÄ ½ÃÀå ±Ô¸ð(°¡Ä¡ ¶Ç´Â ±Ô¸ð, 10¾ï ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, Á¦Ç°º°, 2025-2032³â
  • Á¦Ç°º° ½ÃÀå ¸Å·Â ºÐ¼®

Á¦9Àå ¼¼°èÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå ºÐ¼®, 2019-2032³â, ¿ëµµº°

  • °ú°Å ½ÃÀå ±Ô¸ð(°¡Ä¡ ¶Ç´Â ±Ô¸ð, 10¾ï ´Þ·¯) µ¿Çâ, ¿ëµµº°, 2019-2024³â
  • ÇöÀç ¹× ÇâÈÄ ½ÃÀå ±Ô¸ð(°¡Ä¡ ¶Ç´Â ±Ô¸ð, 10¾ï ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, ¿ëµµº°, 2025-2032³â
  • ¿ëµµº° ½ÃÀå ¸Å·Â ºÐ¼®

Á¦10Àå ¼¼°èÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå ºÐ¼®, 2019-2032³â, Ä¡·á ºÐ¾ßº°

  • °ú°Å ½ÃÀå ±Ô¸ð(°¡Ä¡ ¶Ç´Â ±Ô¸ð, 10¾ï ´Þ·¯) µ¿Çâ, Ä¡·á ºÐ¾ßº°, 2019-2024³â
  • ÇöÀç ¹× ÇâÈÄ ½ÃÀå ±Ô¸ð(°¡Ä¡ ¶Ç´Â ±Ô¸ð, 10¾ï ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, Ä¡·á ºÐ¾ßº°, 2025-2032³â
  • Ä¡·á ºÐ¾ßº° ½ÃÀå ¸Å·Â ºÐ¼®

Á¦11Àå ¼¼°èÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå ºÐ¼®, 2019-2032³â, Áö¿ªº°

  • °ú°Å ½ÃÀå ±Ô¸ð(°¡Ä¡ ¶Ç´Â ±Ô¸ð, 10¾ï ´Þ·¯) µ¿Çâ, Áö¿ªº°, 2019-2024³â
  • ÇöÀç ¹× ÇâÈÄ ½ÃÀå ±Ô¸ð(°¡Ä¡ ¶Ç´Â ±Ô¸ð, 10¾ï ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, Áö¿ªº°, 2025-2032³â
  • Áö¿ªº° ½ÃÀå ¸Å·Â ºÐ¼®

Á¦12Àå ºÏ¹ÌÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå ºÐ¼®, 2019-2032³â

Á¦13Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå 2019-2032³â

Á¦14Àå À¯·´ÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå ºÐ¼®, 2019-2032³â

Á¦15Àå ³²¾Æ½Ã¾ÆÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå ºÐ¼®, 2019-2032³â

Á¦16Àå µ¿¾Æ½Ã¾ÆÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå ºÐ¼®, 2019-2032³â

Á¦17Àå ¿À¼¼¾Æ´Ï¾ÆÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå ºÐ¼®, 2019-2032³â

Á¦18Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Á¶Á¦ ¾à±¹ ½ÃÀå ºÐ¼®, 2019-2032³â

Á¦19Àå ½ÃÀå ±¸Á¶ ºÐ¼®

  • ±â¾÷ °èÃþº° ½ÃÀå ºÐ¼®
  • ½ÃÀå ÁýÁß
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÀÔÁö ºÐ¼®

Á¦20Àå °æÀï ºÐ¼®

  • °æÀï ´ë½Ãº¸µå
  • °æÀï »ó¼¼
    • Fagron
    • Fresenius Kabi AG
    • PharMEDium Services, LLC,
    • Institutional Pharmacy Solutions
    • Cantrell Drug Company
    • Lorraine's Pharmacy
    • B. Braun Melsungen AG Company

Á¦21Àå »ç¿ëµÇ´Â °¡Á¤°ú µÎ¹®ÀÚ¾î

Á¦22Àå Á¶»ç ¹æ¹ý

ksm 25.03.11

Persistence Market Research has recently released a comprehensive report on the worldwide market for compounding pharmacies. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global compounding pharmacies market from 2025 to 2032.

Key Insights:

  • Compounding Pharmacies Market Size (2025E):USD 11.4 Billion
  • Projected Market Value (2032F): USD 16.3 Billion
  • Global Market Growth Rate (CAGR 2025 to 2032): 5.2%

Compounding Pharmacies Market - Report Scope:

Compounding pharmacies specialize in creating customized medications tailored to the specific needs of patients, offering solutions for individuals who require alternative dosage forms, allergen-free medications, or drug combinations not commercially available. These pharmacies cater to hospitals, specialty clinics, long-term care facilities, and individual patients, providing compounded formulations such as topical creams, injectables, oral liquids, and pediatric dosages. Market growth is driven by the rising demand for personalized medicine, increasing drug shortages, and the growing prevalence of chronic diseases requiring specialized treatments.

Market Growth Drivers:

The global compounding pharmacies market is propelled by several key factors, including the rising preference for personalized medicine to address unique patient needs. The increasing incidence of chronic illnesses, such as cancer, cardiovascular diseases, and hormonal imbalances, has heightened demand for customized medications. Additionally, the growing geriatric population requires alternative drug formulations suited for ease of administration. Regulatory support for compounding pharmacies and advancements in pharmaceutical compounding techniques, such as sterile compounding and automation in drug formulation, further boost market expansion. The shortage of certain essential drugs has also led to an increased reliance on compounded medications, particularly in hospital and specialty care settings.

Market Restraints:

Despite promising growth prospects, the compounding pharmacies market faces challenges related to stringent regulatory requirements, concerns over product quality and safety, and high operational costs. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), impose strict guidelines on compounding practices to ensure patient safety. Compliance with these regulations increases costs for pharmacies, particularly for small-scale operators. Additionally, the risk of contamination and variability in drug potency can affect consumer trust and regulatory approvals. The increasing availability of generic and specialty drugs in the commercial market also poses a challenge to the demand for compounded medications.

Market Opportunities:

The compounding pharmacies market presents significant growth opportunities driven by increasing healthcare expenditure, technological advancements in drug compounding, and growing awareness about customized medications. The expansion of home healthcare services and telemedicine platforms allows patients to access compounded medications conveniently. Moreover, innovations in compounding techniques, including 3D drug printing, nanotechnology-based formulations, and the integration of artificial intelligence in medication customization, open new avenues for market players. Strategic partnerships between compounding pharmacies and healthcare providers, along with investments in R&D, will be crucial in capitalizing on emerging opportunities and sustaining market leadership in this evolving industry.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the compounding pharmacies market globally?
  • Which compounding formulations and applications are witnessing increased demand across different healthcare settings?
  • How are regulatory policies shaping the competitive landscape of the compounding pharmacies market?
  • Who are the key players contributing to the compounding pharmacies market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global compounding pharmacies market?

Competitive Intelligence and Business Strategy:

Leading players in the global compounding pharmacies market, including B. Braun Medical Inc., Fagron, Inc., and PharMEDium Services LLC, focus on innovation, quality assurance, and regulatory compliance to gain a competitive edge. These companies invest in R&D to develop advanced compounding solutions, including sterile injectables, hormone replacement therapies, and veterinary compounded medications. Collaborations with hospitals, specialty clinics, and regulatory agencies facilitate market access and ensure adherence to stringent pharmaceutical standards. Additionally, emphasis on automation in compounding processes, training for pharmacists, and consumer education fosters market growth and enhances patient confidence in customized medications.

Key Companies Profiled:

  • B. Braun Medical Inc.
  • Fagron, Inc.
  • PharMEDium Services LLC
  • Pencol Compounding Pharmacy
  • Wedgewood Pharmacy
  • Specialty Compounding LLC
  • Bellevue Pharmacy
  • McGuff Compounding Pharmacy Services, Inc.
  • Rx3 Compounding Pharmacy
  • MEDISCA

Key Segments Covered in Compounding Pharmacies Industry Research

Product:

  • Oral Medication
  • Topical Medications
  • Mouthwashes
  • Suppositories

Application:

  • Medication for Adults
  • Medication for Veterinary
  • Medication for Children
  • Medication for Geriatric

Therapeutic Area:

  • Pain Management
  • Hormone Replacement Therapy

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusion and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Product Innovation / Development Trends

4. Key Success Factors

  • 4.1. Product Adoption Analysis
  • 4.2. Recent Product Approvals/ Launches
  • 4.3. Key Promotional Strategies, By Manufacturers
  • 4.4. Supply Chain Analysis
  • 4.5. Porter's Five Forces Analysis
  • 4.6. PESTEL Analysis
  • 4.7. Regulatory Dynamics

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Overview
    • 5.1.3. Global Personalized Medicine Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Rising geriatric population
    • 5.2.2. Increasing oral medications
    • 5.2.3. Growing public adoption of hormone replacement therapy (HRTs)
    • 5.2.4. Increasing medicine scarcity
    • 5.2.5. Rising pharmaceutical R&D
    • 5.2.6. Rise in pet adoption
    • 5.2.7. Strategic collaborations
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. Revenue By Product
    • 6.1.2. Revenue By Application
    • 6.1.3. Revenue By Therapeutic Area
    • 6.1.4. Revenue By Country
  • 6.2. 2022 Market Scenario

7. Global Compounding Pharmacies Market Demand (Size in US$ Bn) Analysis, 2019 - 2032

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019 - 2024
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2025 - 2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Compounding Pharmacies Market Analysis 2019 - 2032, By Product

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (In Value or Size in US$ Bn) Trend By Product, 2019 - 2024
  • 8.3. Current and Future Market Size (In Value or Size in US$ Bn) Analysis and Forecast By Product, 2025 - 2032
    • 8.3.1. Oral Medications
      • 8.3.1.1. Capsules
      • 8.3.1.2. Tablets
      • 8.3.1.3. Mixtures
      • 8.3.1.4. Lollipops
      • 8.3.1.5. Lozenges
    • 8.3.2. Topical Medications
      • 8.3.2.1. Gels
      • 8.3.2.2. Ointments
      • 8.3.2.3. Creams
      • 8.3.2.4. Lotions
    • 8.3.3. Mouthwashes
    • 8.3.4. Suppositories
  • 8.4. Market Attractiveness Analysis By Product

9. Global Compounding Pharmacies Market Analysis 2019 - 2032, By Application

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (In Value or Size in US$ Bn) Trend By Application, 2019 - 2024
  • 9.3. Current and Future Market Size (In Value or Size in US$ Bn) Analysis and Forecast By Application, 2025 - 2032
    • 9.3.1. Medication for Adults
    • 9.3.2. Medication for Veterinary
    • 9.3.3. Medication for Children
    • 9.3.4. Medication for Geriatric
  • 9.4. Market Attractiveness Analysis By Application

10. Global Compounding Pharmacies Market Analysis 2019 - 2032, By Therapeutic Area

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (In Value or Size in US$ Bn) Trend By Therapeutic Area, 2019 - 2024
  • 10.3. Current and Future Market Size (In Value or Size in US$ Bn) Analysis and Forecast By Therapeutic Area, 2025 - 2032
    • 10.3.1. Pain Management
    • 10.3.2. Hormone Replacement Therapy
  • 10.4. Market Attractiveness Analysis By Therapeutic Area

11. Global Compounding Pharmacies Market Analysis 2019 - 2032, by Region

  • 11.1. Introduction
  • 11.2. Historical Market Size (In Value or Size in US$ Bn) Analysis By Region, 2019 - 2024
  • 11.3. Current Market Size (In Value or Size in US$ Bn) Analysis and Forecast By Region, 2025 - 2032
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. South Asia
    • 11.3.5. East Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa (MEA)
  • 11.4. Market Attractiveness Analysis By Region

12. North America Compounding Pharmacies Market Analysis 2019 - 2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (In Value or Size in US$ Bn) Trend Analysis By Market Taxonomy, 2019 - 2024
  • 12.3. Current and Future Market Size (In Value or Size in US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Product
    • 12.3.3. By Application
    • 12.3.4. By Therapeutic Area
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Product
    • 12.4.3. By Application
    • 12.4.4. By Therapeutic Area
  • 12.5. Market Trends
  • 12.6. Key Market Participants - Intensity Mapping
  • 12.7. Drivers and Restraints - Impact Analysis
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. U.S. Compounding Pharmacies Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Product
        • 12.8.1.2.2. By Application
        • 12.8.1.2.3. By Therapeutic Area
    • 12.8.2. Canada Compounding Pharmacies Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Product
        • 12.8.2.2.2. By Application
        • 12.8.2.2.3. By Therapeutic Area

13. Latin America Compounding Pharmacies Market 2019 - 2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (In Value or Size in US$ Bn) Trend Analysis By Market Taxonomy, 2019 - 2024
  • 13.3. Current and Future Market Size (In Value or Size in US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 13.3.1. By Country
      • 13.3.1.1. Brazil
      • 13.3.1.2. Mexico
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
    • 13.3.2. By Product
    • 13.3.3. By Application
    • 13.3.4. By Therapeutic Area
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Product
    • 13.4.3. By Application
    • 13.4.4. By Therapeutic Area
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Brazil Compounding Pharmacies Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Product
        • 13.8.1.2.2. By Application
        • 13.8.1.2.3. By Therapeutic Area
    • 13.8.2. Mexico Compounding Pharmacies Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Product
        • 13.8.2.2.2. By Application
        • 13.8.2.2.3. By Therapeutic Area
    • 13.8.3. Argentina Compounding Pharmacies Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Product
        • 13.8.3.2.2. By Application
        • 13.8.3.2.3. By Therapeutic Area

14. Europe Compounding Pharmacies Market Analysis, 2019 - 2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (In Value or Size in US$ Bn) Trend Analysis By Market Taxonomy, 2019 - 2024
  • 14.3. Current and Future Market Size (In Value or Size in US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 14.3.1. By Country
      • 14.3.1.1. Germany
      • 14.3.1.2. UK
      • 14.3.1.3. France
      • 14.3.1.4. Italy
      • 14.3.1.5. Russia
      • 14.3.1.6. Spain
      • 14.3.1.7. BENELUX
      • 14.3.1.8. Rest of Europe
    • 14.3.2. By Product
    • 14.3.3. By Application
    • 14.3.4. By Therapeutic Area
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Product
    • 14.4.3. By Application
    • 14.4.4. By Therapeutic Area
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Germany Compounding Pharmacies Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Product
        • 14.8.1.2.2. By Application
        • 14.8.1.2.3. By Therapeutic Area
    • 14.8.2. UK Compounding Pharmacies Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Product
        • 14.8.2.2.2. By Application
        • 14.8.2.2.3. By Therapeutic Area
    • 14.8.3. Russia Compounding Pharmacies Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Product
        • 14.8.3.2.2. By Application
        • 14.8.3.2.3. By Therapeutic Area
    • 14.8.4. Spain Compounding Pharmacies Market Analysis
      • 14.8.4.1. Introduction
      • 14.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.4.2.1. By Product
        • 14.8.4.2.2. By Application
        • 14.8.4.2.3. By Therapeutic Area
    • 14.8.5. France Compounding Pharmacies Market Analysis
      • 14.8.5.1. Introduction
      • 14.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.5.2.1. By Product
        • 14.8.5.2.2. By Application
        • 14.8.5.2.3. By Therapeutic Area
    • 14.8.6. Italy Compounding Pharmacies Market Analysis
      • 14.8.6.1. Introduction
      • 14.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.6.2.1. By Product
        • 14.8.6.2.2. By Application
        • 14.8.6.2.3. By Therapeutic Area
    • 14.8.7. BENELUX Compounding Pharmacies Market Analysis
      • 14.8.7.1. Introduction
      • 14.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.7.2.1. By Product
        • 14.8.7.2.2. By Application
        • 14.8.7.2.3. By Therapeutic Area

15. South Asia Compounding Pharmacies Market Analysis, 2019 - 2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (In Value or Size in US$ Bn) Trend Analysis By Market Taxonomy, 2019 - 2024
  • 15.3. Current and Future Market Size (In Value or Size in US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Malaysia
      • 15.3.1.4. Thailand
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Product
    • 15.3.3. By Application
    • 15.3.4. By Therapeutic Area
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Product
    • 15.4.3. By Application
    • 15.4.4. By Therapeutic Area
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. India Compounding Pharmacies Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Product
        • 15.8.1.2.2. By Application
        • 15.8.1.2.3. By Therapeutic Area
    • 15.8.2. Indonesia Compounding Pharmacies Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Product
        • 15.8.2.2.2. By Application
        • 15.8.2.2.3. By Therapeutic Area
    • 15.8.3. Malaysia Compounding Pharmacies Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Product
        • 15.8.3.2.2. By Application
        • 15.8.3.2.3. By Therapeutic Area
    • 15.8.4. Thailand Compounding Pharmacies Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Product
        • 15.8.4.2.2. By Application
        • 15.8.4.2.3. By Therapeutic Area

16. East Asia Compounding Pharmacies Market Analysis, 2019 - 2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (In Value or Size in US$ Bn) Trend Analysis By Market Taxonomy, 2019 - 2024
  • 16.3. Current and Future Market Size (In Value or Size in US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 16.3.1. By Country
      • 16.3.1.1. China
      • 16.3.1.2. Japan
      • 16.3.1.3. South Korea
    • 16.3.2. By Product
    • 16.3.3. By Application
    • 16.3.4. By Therapeutic Area
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Product
    • 16.4.3. By Application
    • 16.4.4. By Therapeutic Area
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. China Compounding Pharmacies Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Product
        • 16.8.1.2.2. By Application
        • 16.8.1.2.3. By Therapeutic Area
    • 16.8.2. Japan Compounding Pharmacies Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Product
        • 16.8.2.2.2. By Application
        • 16.8.2.2.3. By Therapeutic Area
    • 16.8.3. South Korea Compounding Pharmacies Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Product
        • 16.8.3.2.2. By Application
        • 16.8.3.2.3. By Therapeutic Area

17. Oceania Compounding Pharmacies Market Analysis, 2019 - 2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (In Value or Size in US$ Bn) Trend Analysis By Market Taxonomy, 2019 - 2024
  • 17.3. Current and Future Market Size (In Value or Size in US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Product
    • 17.3.3. By Application
    • 17.3.4. By Therapeutic Area
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Product
    • 17.4.3. By Application
    • 17.4.4. By Therapeutic Area
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. Australia Compounding Pharmacies Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Product
        • 17.8.1.2.2. By Application
        • 17.8.1.2.3. By Therapeutic Area
    • 17.8.2. New Zealand Compounding Pharmacies Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Product
        • 17.8.2.2.2. By Application
        • 17.8.2.2.3. By Therapeutic Area

18. Middle East & Africa (MEA) Compounding Pharmacies Market Analysis, 2019 - 2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (In Value or Size in US$ Bn) Trend Analysis By Market Taxonomy, 2019 - 2024
  • 18.3. Current and Future Market Size (In Value or Size in US$ Bn) Analysis and Forecast By Market Taxonomy, 2025 - 2032
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Turkey
      • 18.3.1.3. South Africa
      • 18.3.1.4. North Africa
      • 18.3.1.5. Rest of MEA
    • 18.3.2. By Product
    • 18.3.3. By Application
    • 18.3.4. By Therapeutic Area
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Product
    • 18.4.3. By Application
    • 18.4.4. By Therapeutic Area
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. GCC Countries Compounding Pharmacies Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Product
        • 18.8.1.2.2. By Application
        • 18.8.1.2.3. By Therapeutic Area
    • 18.8.2. Turkey Compounding Pharmacies Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Product/p>
        • 18.8.2.2.2. By Application
        • 18.8.2.2.3. By Therapeutic Area
    • 18.8.3. South Africa Compounding Pharmacies Market Analysis
      • 18.8.3.1. Introduction
      • 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.3.2.1. By Product
        • 18.8.3.2.2. By Application
        • 18.8.3.2.3. By Therapeutic Area
    • 18.8.4. North Africa Compounding Pharmacies Market Analysis
      • 18.8.4.1. Introduction
      • 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.4.2.1. By Product
        • 18.8.4.2.2. By Application
        • 18.8.4.2.3. By Therapeutic Area

19. Market Structure Analysis

  • 19.1. Market Analysis by Tier of Companies
  • 19.2. Market Concentration
  • 19.3. Market Share Analysis of Top Players
  • 19.4. Market Presence Analysis
    • 19.4.1. Regional footprint of Players
    • 19.4.2. Product foot print by Players
    • 19.4.3. Channel Foot Print by Players

20. Competition Analysis

  • 20.1. Competition Dashboard
  • 20.2. Competition Deep Dive
    • 20.2.1. Fagron
      • 20.2.1.1. Overview
      • 20.2.1.2. Product Portfolio
      • 20.2.1.3. Key Financials
      • 20.2.1.4. Sales Footprint
      • 20.2.1.5. SWOT Analysis
      • 20.2.1.6. Strategy Overview
        • 20.2.1.6.1. Marketing Strategy
        • 20.2.1.6.2. Product Strategy
        • 20.2.1.6.3. Channel Strategy
    • 20.2.2. Fresenius Kabi AG
      • 20.2.2.1. Overview
      • 20.2.2.2. Product Portfolio
      • 20.2.2.3. Key Financials
      • 20.2.2.4. Sales Footprint
      • 20.2.2.5. SWOT Analysis
      • 20.2.2.6. Strategy Overview
        • 20.2.2.6.1. Marketing Strategy
        • 20.2.2.6.2. Product Strategy
        • 20.2.2.6.3. Channel Strategy
    • 20.2.3. PharMEDium Services, LLC,
      • 20.2.3.1. Overview
      • 20.2.3.2. Product Portfolio
      • 20.2.3.3. Key Financials
      • 20.2.3.4. Sales Footprint
      • 20.2.3.5. SWOT Analysis
      • 20.2.3.6. Strategy Overview
        • 20.2.3.6.1. Marketing Strategy
        • 20.2.3.6.2. Product Strategy
        • 20.2.3.6.3. Channel Strategy
    • 20.2.4. Institutional Pharmacy Solutions
      • 20.2.4.1. Overview
      • 20.2.4.2. Product Portfolio
      • 20.2.4.3. Key Financials
      • 20.2.4.4. Sales Footprint
      • 20.2.4.5. SWOT Analysis
      • 20.2.4.6. Strategy Overview
        • 20.2.4.6.1. Marketing Strategy
        • 20.2.4.6.2. Product Strategy
        • 20.2.4.6.3. Channel Strategy
    • 20.2.5. Cantrell Drug Company
      • 20.2.5.1. Overview
      • 20.2.5.2. Product Portfolio
      • 20.2.5.3. Key Financials
      • 20.2.5.4. Sales Footprint
      • 20.2.5.5. SWOT Analysis
      • 20.2.5.6. Strategy Overview
        • 20.2.5.6.1. Marketing Strategy
        • 20.2.5.6.2. Product Strategy
        • 20.2.5.6.3. Channel Strategy
    • 20.2.6. Lorraine's Pharmacy
      • 20.2.6.1. Overview
      • 20.2.6.2. Product Portfolio
      • 20.2.6.3. Key Financials
      • 20.2.6.4. Sales Footprint
      • 20.2.6.5. SWOT Analysis
      • 20.2.6.6. Strategy Overview
        • 20.2.6.6.1. Marketing Strategy
        • 20.2.6.6.2. Product Strategy
        • 20.2.6.6.3. Channel Strategy
    • 20.2.7. B. Braun Melsungen AG Company
      • 20.2.7.1. Overview
      • 20.2.7.2. Product Portfolio
      • 20.2.7.3. Key Financials
      • 20.2.7.4. Sales Footprint
      • 20.2.7.5. SWOT Analysis
      • 20.2.7.6. Strategy Overview
        • 20.2.7.6.1. Marketing Strategy
        • 20.2.7.6.2. Product Strategy
        • 20.2.7.6.3. Channel Strategy

21. Assumptions and Acronyms Used

22. Research Methodology

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦